Search

Your search keyword '"Bargo, Danielle"' showing total 29 results
Start Over Author "Bargo, Danielle"
29 results on '"Bargo, Danielle"'

3. Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study

Author

Mpofu, Philani, primary, Kent, Seamus, additional, Jónsson, Páll, additional, Pittell, Harlan, additional, Groves, Brad, additional, Altomare, Ivy, additional, Copeland, Amanda, additional, Baxi, Shrujal, additional, Bargo, Danielle, additional, Sujenthiran, Arun, additional, and Adamson, Blythe, additional

Published
2023
Full Text
View/download PDF

7. Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer

Author

Wang, Xiaoliang, Adamson, Blythe J, Briggs, Andrew, Tan, Katherine, Bargo, Danielle, Ghosh, Shuhag, Baxi, Shrujal, and Ramsey, Scott

Abstract

OBJECTIVES: This study aimed to demonstrate enhanced survival extrapolation methods using electronic health record-derived real-world data (RWD). METHODS: The study population included patients diagnosed of ER+/HER2- metastatic breast cancer who started first-line treatment with anastrozole or letrozole between November 18, 2014, and November 18, 2015. Two patient cohorts were constructed: a clinical trial cohort from digitized MONARCH-3 clinical trial results and a RWD cohort from a deidentified electronic health record-derived database. RWD patients were weighted to trial baseline covariate distributions. Standard parametric approaches were applied to trial data and a "best-fit" model was selected. We demonstrate traditional and enhanced hybrid (pooling with weighted RWD at start, 75%, or end of trial) extrapolation approaches. RESULTS: Observed and estimated 5-year progression-free survival (PFS) rates in extrapolating the trial control arm (n = 165) were comparable across all methods. Compared with the observed 5-year mean PFS in the RWD cohort (n = 118) of 20.4 months (95% confidence interval [CI] 16.9-23.8), there was some variation among studied methods. Best-fit standard parametric model (log-normal) had 5-year mean PFS of 21.3 months (95% CI 18.2-24.9), and for the hybrid methods in order of estimate conservativeness was start of trial (20.8 months; 95% CI 18.5-23.2), 75% of trial (21.3 months; 95% CI 18.1-24.5), and end of trial (21.8 months; 95% CI 18.8-25.2). CONCLUSIONS: Our study leverages RWD to enhance long-term survival extrapolation. Future use cases should include applying patient eligibility criteria, weighting on baseline characteristics, and choice of time window to add RWD to trial data.

Published
2021

10. Additional file 1 of Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England

Author

Campbell, Helen E., Stokes, Elizabeth A., Bargo, Danielle N., Curry, Nicola, Lecky, Fiona E., Edwards, Antoinette, Woodford, Maralyn, Seeney, Frances, Eaglestone, Simon, Brohi, Karim, Gray, Alastair M., and Stanworth, Simon J.

Abstract

This file provides supplementary information on the costing methods used in the study and on the techniques used to handle missing resource use data [ 17 , 18 , 29 , 30 ]. (DOCX 30 kb)

Published
2021
Full Text
View/download PDF

11. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.

Author

Long, Millie D., Cohen, Russell D., Smith, Timothy W., DiBonaventura, Marco, Gruben, David, Bargo, Danielle, Salese, Leonardo, and Quirk, Daniel

Subjects
PATIENT compliance, ULCERATIVE colitis, BIOTHERAPY, BIOLOGICALS, RETROSPECTIVE studies
Abstract

Background: Biologic therapies are often used in patients with ulcerative colitis (UC) who are nonresponsive to conventional treatments. However, nonresponse or loss of response to biologics often occurs, leading to dose escalation, combination therapy, and/or treatment switching. We investigated real-world treatment patterns of biologic therapies among patients with UC in the USA. Methods: This study analyzed data from the IBM® MarketScan® Commercial and Medicare Supplemental Databases (medical/pharmacy claims for >250 million patients in the USA) to identify patients with UC initiating a biologic therapy (adalimumab, infliximab, golimumab, or vedolizumab) with 12 months of follow-up post-initiation. Key measures were patient baseline characteristics, dose escalation (average maintenance dose >20% higher than label), adherence (proportion of days covered), and ulcerative colitis-related healthcare costs in the 12 months following biologic therapy initiation. Results: Of 2,331 patients included in the study (adalimumab [N = 1,291], infliximab [N = 810], golimumab [N = 127], and vedolizumab [N = 103]), 28.1% used concomitant immunosuppressant therapy within 12 months post-initiation. Overall, 23.6% (adalimumab), 34.8% (infliximab), 9.9% (golimumab), and 39.2% (vedolizumab) of patients dose escalated within 12 months. Patients who dose escalated incurred USD 20,106 higher total UC-related healthcare costs over 12 months than those who did not. Adherence (covariate-adjusted proportion of days covered) ranged from 0.63 to 0.73, and 39.3% of patients discontinued within 12 months (median treatment duration = 112 days). Conclusion: Dose escalation was common, and incurred higher costs, in patients with UC initiating biologic therapies. Suboptimal adherence and/or discontinuation within 12 months of initiation occurred frequently, highlighting the challenges in managing these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Conversation Aid Tool

Author

Bentley, Sarah, primary, Johnson, Chloe, additional, Exall, Elizabeth, additional, Brohan, Elaine, additional, Lawrance, Rachael, additional, Bennett, Bryan, additional, Bargo, Danielle, additional, Zanotti, Giovanni, additional, Staehler, Michael, additional, and Stewart, Grant D., additional

Published
2021
Full Text
View/download PDF

14. Improving patient-clinician communication following nephrectomy in renal cell carcinoma: Development, content validation and pilot testing of a conversation aid tool

Author

Bentley, Sarah, primary, Johnson, Chloe, additional, Exall, Elizabeth, additional, Brohan, Elaine, additional, Lawrance, Rachael, additional, Bennett, Bryan, additional, Bargo, Danielle, additional, Zanotti, Giovanni, additional, Staehler, Michael, additional, and Stewart, Grant D, additional

Published
2021
Full Text
View/download PDF

16. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis

Author

Brookes, Matthew J, primary, Waller, John, additional, Cappelleri, Joseph C, additional, Modesto, Irene, additional, DiBonaventura, Marco D, additional, Bohm, Natalie, additional, Mokgokong, Ruth, additional, Massey, Olivia, additional, Wood, Robert, additional, and Bargo, Danielle, additional

Published
2020
Full Text
View/download PDF

18. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs

Author

Dignass, Axel, primary, Waller, John, additional, Cappelleri, Joseph C., additional, Modesto, Irene, additional, Kisser, Agnes, additional, Dietz, Lena, additional, DiBonaventura, Marco, additional, Wood, Robert, additional, May, Melanie, additional, Libutzki, Berit, additional, and Bargo, Danielle, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results